DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
SJG-136 is an investigational drug.
There have been 4 clinical trials for SJG-136. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Neoplasms, Leukemia, Lymphoid, and Precursor Cell Lymphoblastic Leukemia-Lymphoma. The leading clinical trial sponsors are National Cancer Institute (NCI) and [disabled in preview].
Recent Clinical Trials for SJG-136
|SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin||National Cancer Institute (NCI)||Phase 2|
|SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Phase 1|
|SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery||National Cancer Institute (NCI)||Phase 1|